206 related articles for article (PubMed ID: 32298002)
1. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.
Moolla A; de Boer J; Pavlov D; Amin A; Taylor A; Gilligan L; Hughes B; Ryan J; Barnes E; Hassan-Smith Z; Grove J; Aithal GP; Verrijken A; Francque S; Van Gaal L; Armstrong MJ; Newsome PN; Cobbold JF; Arlt W; Biehl M; Tomlinson JW
Aliment Pharmacol Ther; 2020 Jun; 51(11):1188-1197. PubMed ID: 32298002
[TBL] [Abstract][Full Text] [Related]
2. Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study.
Miller H; Harman D; Aithal GP; Manousou P; Cobbold JF; Parker R; Sheridan D; Newsome PN; Karpe F; Neville M; Arlt W; Sitch AJ; Korbonits M; Biehl M; Alazawi W; Tomlinson JW
BMJ Open; 2024 Jan; 14(1):e074918. PubMed ID: 38238179
[TBL] [Abstract][Full Text] [Related]
3. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
[TBL] [Abstract][Full Text] [Related]
4. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
5. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
8. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
[TBL] [Abstract][Full Text] [Related]
9. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
[TBL] [Abstract][Full Text] [Related]
10. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
[TBL] [Abstract][Full Text] [Related]
11. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.
Kechagias S; Ekstedt M; Simonsson C; Nasr P
Hormones (Athens); 2022 Sep; 21(3):349-368. PubMed ID: 35661987
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
14. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive distinction of non-alcoholic fatty liver disease using urinary volatile organic compound analysis: early results.
Arasaradnam RP; McFarlane M; Daulton E; Westenbrink E; O'Connell N; Wurie S; Nwokolo CU; Bardhan KD; Savage RS; Covington JA
J Gastrointestin Liver Dis; 2015 Jun; 24(2):197-201. PubMed ID: 26114180
[TBL] [Abstract][Full Text] [Related]
16. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
Cengiz M; Ozenirler S
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
[TBL] [Abstract][Full Text] [Related]
17. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
[TBL] [Abstract][Full Text] [Related]
18. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease.
Catania R; Furlan A; Smith AD; Behari J; Tublin ME; Borhani AA
Eur Radiol; 2021 Jan; 31(1):256-263. PubMed ID: 32757050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
